

- Dopamine receptor antagonists
adverse effects of, 565
for migraine, 2588, 2591–2592, 2592t
for nausea and vomiting, 260, 260t
parenteral, 2592, 2592t
- Dopa-responsive dystonia, 434e-2t, 2620
- Doppler ultrasound, 270e-2, 270e-2f. *See also* Echocardiography
- Droripenem
for anaerobic bacterial infections, 1101
indications for, 941
for intraabdominal infections, 767t
for *P. aeruginosa* infections, 1045t
resistance to, 933
- Dormancy, in cancer cells, 103e-6
- Dornase, 1696
- Dorsal midbrain syndrome (Parinaud's syndrome). *See* Parinaud's syndrome/complex
- Dorsal respiratory group, 1720
- Dorsal root ganglia, 87, 87f, 88
- Dorsal root ganglionopathy, 618
- Dose-limiting toxicity (DLT), 103e-5
- Dosulepin, 2594t
- DOTS/DOTS-Plus strategy, for tuberculosis, 12, 1121
- Double-balloon endoscopy/enteroscopy
indications for, 1878, 1879t
small-bowel, 346e-1v, 1881, 1883f, 1897f
- Doublecortin, 2545t
- Double-dip sign, 226
- Double minute, 101e-3
- Downbeat nystagmus, 211
- Down's syndrome (trisomy 21)
AD and, 2600–2601
AML in, 678
autoimmune polyendocrine deficiencies in, 2348
chromosome abnormalities in, 83e-1, 83e-4
clinical features of, 83e-4, 1654
myelodysplasia in, 670
oral manifestations of, 236
transient myeloproliferative disorder in, 135e-7
- Doxazosin, 1624t, 1649
- Doxepin
adverse effects of, 2710t
for angioedema, 2119
for insomnia, 191
overdosage/poisoning with, 473e-9t, 473e-10t, 2764t
for pain, 91t
for pruritus, 345
therapeutic monitoring of, 2764t
for urticaria, 2119
- Doxorubicin
action of, 103e-13
adverse effects of, 103e-10t, 103e-13
acral erythema, 380
cardiotoxicity, 103e-13, 1563, 1567
late, 620t, 621
myelosuppression, 103e-13
neurologic, 1793
for bladder cancer, 577
for breast cancer, 528, 529
drug interactions of, 103e-10t
for Ewing's sarcoma, 119e-4
for gastric lymphoma, 536
for hepatocellular carcinoma, 550
for insulinoma, 2338
for lung cancer, 522
for osteosarcoma, 119e-3
for ovarian cancer, 594
for pNETS, 574
in pregnancy, 124e-4
for salivary gland tumors, 506
for soft tissue sarcoma, 119e-2
- Doxycycline
for acne rosacea, 352
for acne vulgaris, 352
for actinomycosis, 1091t
action of, 930, 931t, 943
adverse effects of, 361, 943, 1380t
for anthrax, 261e-3, 261e-5t
for bacillary angiomatosis/peliosis, 832t, 1081t
for *Bartonella* endocarditis, 1081t
for *Bartonella* infection prophylaxis in HIV infection, 1252t
for bite-wound infections, 167e-3, 167e-3t, 832t
for *Brucella* infections, 194e-4
for *C. trachomatis* infections, 1171, 1172
for cat-scratch disease, 1081t
for cholera, 1064
for community-acquired pneumonia, 808t
for donovanosis, 198e-2t
for ehrlichioses, 1160
for endemic treponematoses, 207e-2
for epidemic typhus, 1159
for gonococcal infections, 1009t
for human granulocytotropic anaplasmosis, 1161
indications for, 940t, 943
for infective endocarditis, 823t
for *Legionella* infections, 1020t
for leptospirosis, 1145t
for Lyme disease, 836, 1153, 1153f
for Lyme disease prophylaxis, 2745
for lymphatic filariasis, 1419
for *M. pneumoniae* infections, 1164
for malaria, 1378t, 1380t
for malaria prophylaxis, 796t, 1383, 1383t
for MRSA infections, 345, 962t
for mucopurulent cervicitis, 876
for onchocerciasis, 1421
for pelvic inflammatory disease, 878, 878t, 879
for pericardial effusion, 474
for plague prophylaxis, 1075t
for plague treatment, 261e-5, 261e-5t, 261e-6, 1075
for pleural effusion, 474
prophylactic, 945t
for Q fever, 1162
for reactive arthritis, 2175
for relapsing fever, 1148, 1148f
resistance to, 931t, 940t
for rickettsialpox, 1158
for Rocky Mountain spotted fever, 780t, 782, 1157
for scrub typhus, 1159
for sinusitis, 227t
for staphylococcal skin/soft tissue infections, 962t
for syphilis, 1139, 1139t
for tularemia, 261e-5t, 261e-7
for Whipple's disease, 1094
- Doxylamine, 261, 473e-8t
- DPP-IV (dipeptidyl peptidase-4) inhibitors, 2414–2415, 2414t, 2416
- DQB genes, 373e-7–8
- Dracunculus medinensis* (guinea worm)/dracunculiasis
clinical features of, 829, 837, 1422
diagnosis of, 245e-3t, 1422
epidemiology of, 1422
life cycle of, 245e-3t, 1422
prevention of, 1423
treatment of, 246e-13, 1423
- Dravet's syndrome, 2545t
- Drawer sign, 2222
- DRB genes, 373e-2, 373e-7
- DRESS (drug reaction with eosinophilia and systemic symptoms). *See* Drug-induced hypersensitivity syndrome (DIHS)
- Dressing apraxia, 182
- Dressings, for chronic venous disease, 1652
- Driving ability/privileges, 188, 2559
- Dronabinol, 81, 469e-3
- Dronedarone
adverse effects of, 1480t, 1489
for arrhythmias, 1480t, 1489, 1499, 1514
dosage of, 1480t
drug interactions of, 205e-3
pharmacology of, 1480t
- Drop attacks, 165. *See also* Fall(s)
- Dropped head syndrome, 462e-1
- Drospirenone, 310, 334
- Drowsiness, 61, 1771
- Droxidopa, 2644
- Drp1, 444e-9
- Drug(s)
adverse reactions to. *See* Adverse drug reactions; Drug-induced illness
benefits of, 32
bioavailability of, 33
clearance of, 35
development of
for cancer, 103e-5–6, 103e-6f
genomics in, 775–776
systems biology and, 87e-2–3
targeted agents, 103e-6
target molecules in, 32
distribution of, 34–35
dose-response relations, 32, 32f
dose selection, 36
elimination of, 35
failure of efficacy of, 36
genetic determinants of response to, 38
half-life of, 34, 35f
indications for, 32
interactions between. *See* Drug interactions
intravenous administration of, 35
medication errors, 3
metabolism of
active metabolites in, 35
enzymes in, 935
first-pass effect, 33–34, 33f, 935
genetic variations in, 38–41, 38f, 39t
gut microbiota and, 86e-7
new, skews in research for, 13e-4
overdosage of. *See* Poisoning/drug overdose
plasma concentration of, 33–34, 33f, 36–37, 37f
prescription, use in U.S., 377
risks of, 32
slow-release formulation of, 33
sustained-release formulation of, 33
therapeutic monitoring of, 2764–2766t
time-of-day effects on, 194
- Drug-dependent antibodies, 727
- Drug disposition. *See* Drug(s), metabolism of
- Drug dosage
dosing interval, 34
in elderly, 38
in heart failure and shock, 37
in kidney disease, 37
in liver disease, 37
loading dose, 35, 35f
maintenance dose, 36
plasma concentration as guide to therapy, 35
selection of, 36–37
- Drug fever, 370
- Drug history, 44
- Drug-induced hypersensitivity syndrome (DIHS)
clinical features of, 131t, 134, 138, 370, 382
diagnosis of, 382, 384t
drugs associated with, 382
etiology of, 131t, 353, 382
genetic considerations in, 378
immune pathways of, 378, 378t
skin manifestations of, 25e-12f, 131t
time of onset, 382
- Drug-induced illness. *See also* Adverse drug reactions; Poisoning/drug overdose
anaphylaxis, 381
autonomic dysfunction, 2639, 2640t
cutaneous, 103e-26, 127, 377
cross-sensitivity in, 384–385
delayed hypersensitivity, 377–378
desensitization for prevention of, 384
diagnosis of, 383, 383t
drug selection after, 383–384
exacerbation or induction of dermatologic disease, 378–379
exanthematous eruption, 25e-2f, 128t
exanthems, 362, 362t
fixed drug eruption, 381, 382f